Table 10Incidence of SLN metastases according to AJCC staging system

AuthorCountrypN0(i+) % (n with positive nodes/N tested)pN1(mic) % (n with positive nodes/N tested)pN1 % (n with positive nodes/N tested)
DCIS
Katz, 2006267United States4% (4; 110)4% (4; 110)0% (0; 110)
Leidenius, 2006268Finland4% (3; 73)1% (1; 73)1% (1; 73)
Tan, 2007276Canada6% (2; 32)6% (2; 32)0% (0; 32)
Genta, 2007272Italy6% (2; 34)0% (0; 34)0% (0; 34)
Moore, 2007275United States8% (36; 470)0.9% (4; 470)0.6% (3; 470)
Domiquez, 2008237United States9% (15; 159)0.6% (1; 159)0% (0; 159)
Intra, 2008278Italy0.5% (4; 854)0.8% (7; 854)0.6% (5; 854)
Sakr, 2008284France4% (4; 110)0% (0; 110)3% (3; 110)
Overall pooled with random effects (95% CI)4.2% (2.2%; 7.7%)1.5% (0.8%; 2.8%)0.9% (0.5%; 1.5%)
DCISM
Sakr, 2008284France0% (0; 54)4% (2; 54)0% (0; 54)
Katz, 2006267United States5% (1; 21)5% (1; 21)0% (0; 21)
Leidenius, 2006268Finland9% (1; 11)0% (0; 11)0% (0; 11)
Gray, 2006268United States3% (2; 77)3% (2; 77)3% (2; 77)
Overall (95% CI)3.5% (1.4%, 8.4%)3.4% (1.5%; 7.7%)2.3% (0.8%; 6.5%)
DCIS/DCISM*
Murphy, 2008279United States8% (25; 322)1% (3; 322)0.3% (1; 322)
Yen, 2005264United States1% (2; 141)6% (9; 141)2% (3; 141)
Overall pooled with random effects (95% CI)3.8% (0.7%; 18%)2.6% (0.4%; 15%)0.6% (0.2%; 1.6%)
*

DCIS and DCISM were analyzed together

Significant heterogeneity

From: 3, Results

Cover of Diagnosis and Management of Ductal Carcinoma in Situ (DCIS)
Diagnosis and Management of Ductal Carcinoma in Situ (DCIS).
Evidence Reports/Technology Assessments, No. 185.
Virnig BA, Shamliyan T, Tuttle TM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.